Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Dow
Queensland Health
Teva
Daiichi Sankyo
Mallinckrodt
Deloitte
Cipla
Cantor Fitzgerald

Generated: May 25, 2018

DrugPatentWatch Database Preview

KAFOCIN Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

When do Kafocin patents expire, and when can generic versions of Kafocin launch?

Kafocin is a drug marketed by Lilly and is included in one NDA.

The generic ingredient in KAFOCIN is cephaloglycin. Additional details are available on the cephaloglycin profile page.
Summary for KAFOCIN
Drug patent expirations by year for KAFOCIN
Medical Subject Heading (MeSH) Categories for KAFOCIN
Synonyms for KAFOCIN
(6R,7R)-3-(acetoxymethyl)-7-[[(2R)-2-amino-2-phenyl-acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6R,7R)-3-(acetoxymethyl)-7-{[(2R)-2-amino-2-phenylacetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6R,7R)-3-(acetyloxymethyl)-7-[[(2R)-2-amino-2-phenylacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6R,7R)-3-[(acetyloxy)methyl]-7-[(2R)-2-amino-2-phenylacetamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6R,7R)-3-[(acetyloxy)methyl]-7-{[(2R)-2-amino-2-phenylacetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
3-((Acetyloxy)methyl)-7-((aminophenylacetyl)amino)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid
3-acetoxymethyl-7beta-[(2R)-2-amino-2-phenylacetamido]-3,4-didehydrocepham-4-carboxylic acid
3577-01-3
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-((acetyloxy)methyl)-7-((aminophenylacetyl)amino)-8-oxo-, (6R-(6alpha,7beta(R*)))-
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(2-amino-2-phenylacetamido)-3-(hydroxymethyl)-8-oxo-, acetate (ester), D-
7-(2-Amino-2-phenylacetamido)-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid acetate (ester)
7-(2-Amino-2-phenylacetamido)-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)octane-2-carboxylic acid acetate inner salt
7-(2-Amino-2-phenylacetamido)-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)octane-2-carboxylic acid, acetate inner salt
7-(2-D-alpha-Aminophenylacetamido)cephalosporanic acid
7-(D-2-Amino-2-phenylacetamido)-3-acetoxymethyl-delta(3)-cephem-4-carboxylic acid
7-(D-2-Amino-2-phenylacetamido)-3-acetoxymethyl-delta(sup 3)-cephem-4-carboxylic acid
7-(D-2-Amino-2-phenylacetamido)-3-acetoxymethyl-delta(sup3)-cephem-4-carboxylic acid
7-(D-alpha-Aminophenyl-acetamido)cephalosporanic acid
AC1L2DJO
AC1Q6LOC
AN-5594
API0001931
C13440
C18H19N3O6S
Cefaloglicina
Cefaloglicina [INN-Spanish]
Cefaloglycin
Cefaloglycin (JAN)
Cefaloglycine
Cefaloglycine [INN-French]
Cefaloglycinum
Cefaloglycinum [INN-Latin]
CEG
CEPHALOGLYCIN
CEPHALOGLYCIN (4-[(3-Chlorophenyl)Amino]-4-Oxobutanoic Acid)
Cephaloglycin (anhydrous)
Cephaloglycin anhdyous
Cephaloglycin anhydrous
Cephaloglycinanhdyous
Cephaloglycine
Cephaoglycin acid
CHEBI:34613
CHEMBL1200971
D-(-)-Cephaloglycin
D-Cephaloglycine
D01949
D07WZH
DB00689
DTXSID4022781
EINECS 222-696-7
Epitope ID:174844
FUBBGQLTSCSAON-PBFPGSCMSA-N
HD2D469W6U
HE067083
HE288052
HSDB 3214
Kefglycin
Lilly 39435
LS-149962
SCHEMBL2947
UNII-HD2D469W6U
ZINC3830503

US Patents and Regulatory Information for KAFOCIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lilly KAFOCIN cephaloglycin CAPSULE;ORAL 050219-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
US Department of Justice
UBS
Mallinckrodt
Cerilliant
Federal Trade Commission
US Army
Cipla
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.